We are live on ! Find out more
YMAB

Y-mAbs Therapeutics

Delisted

YMAB was delisted on the 15th of September, 2025.

97 hedge funds and large institutions have $394M invested in Y-mAbs Therapeutics in 2021 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 38 increasing their positions, 28 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

36% more repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 28

7% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 15

0% more funds holding

Funds holding: 9797 (0)

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

1.25% less ownership

Funds ownership: 60.22%58.97% (-1.3%)

45% less capital invested

Capital invested by funds: $716M → $394M (-$322M)

Holders
97
Holders Change
Holders Change %
0%
% of All Funds
1.49%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
16
Increased
38
Reduced
28
Closed
15
Calls
Puts
Net Calls
Net Calls Change

YMAB Hedge Fund Activity: Q4 2021 in Review

97 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Y-mAbs Therapeutics (YMAB) for Q4 2021, worth a combined $394M — down 45% from $716M a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new YMAB positions and 15 closed out — a net gain of 1 holder — while 38 added to existing stakes and 28 trimmed.

The largest buyer was AllianceBernstein, adding an estimated $11.2M. The largest seller was First Light Asset Management, exiting entirely with an estimated $16.5M sold.

  • 97 institutional investors held Y-mAbs Therapeutics (YMAB) as of Q4 2021, unchanged from Q3 2021.
  • Funds reported $394M of Y-mAbs Therapeutics stock for Q4 2021, down 45% quarter-over-quarter.
  • 16 funds opened new Y-mAbs Therapeutics positions in Q4 2021 and 15 closed out, a net change of +1 holder.
  • The largest Y-mAbs Therapeutics buyer in Q4 2021 was AllianceBernstein, an estimated $11.2M added.
  • The largest Y-mAbs Therapeutics seller in Q4 2021 was First Light Asset Management, an estimated $16.5M sold.

Based on aggregated 13F filings for Q4 2021.